Overview

Evaluation of the Effect of AVE0657 on Obstructive Sleep Apnea

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the activity of 4 escalating doses of AVE0657 in comparison to placebo in patients with Obstructive Sleep Apnea Hypopnea Syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi